Extended Autoimmune Liver Profile at Test Zone Diagnostic Center

Extended Autoimmune Liver Profile at Test Zone Diagnostic Center

The Extended Autoimmune Liver Profile at Test Zone Diagnostic Center is a specialized, comprehensive panel of serological assays designed to identify specific autoantibodies associated with autoimmune liver diseases (AILD). Autoimmune liver diseases represent a complex spectrum of chronic inflammatory disorders where the body’s immune system mistakenly targets hepatocytes or biliary epithelial cells. This advanced diagnostic profile is crucial for distinguishing between various autoimmune conditions, such as Autoimmune Hepatitis (AIH), Primary Biliary Cholangitis (PBC), and Primary Sclerosing Cholangitis (PSC), which often present with overlapping clinical and biochemical features.

Using state-of-the-art laboratory technology, including Indirect Immunofluorescence (IIF), Enzyme-Linked Immunosorbent Assay (ELISA), and Line Immunoassays (LIA), the pathology department at Test Zone Diagnostic Center in Peshawar, Pakistan, evaluates patient serum for a wide array of highly specific autoantibodies. These include Antinuclear Antibodies (ANA), Smooth Muscle Antibodies (SMA), Antimitochondrial Antibodies (AMA-M2), Liver Kidney Microsomal Type 1 (LKM-1) antibodies, Liver Cytosol Type 1 (LC-1) antibodies, and Soluble Liver Antigen/Liver-Pancreas (SLA/LP) antibodies. Identifying these markers is essential for establishing an early, accurate diagnosis, guiding therapeutic decisions, and preventing the progression of liver disease to cirrhosis or liver failure.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the highest accuracy and prevent potential interference with the immunological assays, patients undergoing the Extended Autoimmune Liver Profile at Test Zone Diagnostic Center should follow these preparation guidelines:

• Fasting Requirements: While fasting is not strictly mandatory for antibody testing, a fasting period of 8 to 12 hours is highly recommended. This helps prevent lipemia (excess fat in the blood), which can interfere with the optical readings of ELISA and line immunoassay platforms.
• Medication Disclosure: Patients must inform the laboratory staff and their referring physician about all current medications, particularly immunosuppressants, corticosteroids, or biological therapies, as these can suppress antibody levels and potentially lead to false-negative results.
• Hydration: Adequate hydration is encouraged prior to the blood draw, as it facilitates easier venous access and ensures an optimal sample volume.
• Avoid Alcohol: Patients should refrain from consuming alcohol for at least 24 hours before the test, as alcohol can acutely alter liver enzyme levels and affect overall metabolic parameters.

During the Procedure

The Extended Autoimmune Liver Profile is a straightforward laboratory investigation requiring a standard peripheral blood sample. The procedure is conducted by highly trained phlebotomists at Test Zone Diagnostic Center:

• Patient Identification and Verification: The phlebotomist will verify the patient’s identity, clinical indications, and adherence to preparation guidelines.
• Venipuncture Site Selection: The patient is seated comfortably, and a suitable vein, typically in the antecubital fossa (inner elbow), is selected.
• Aseptic Technique: The skin at the puncture site is thoroughly cleansed with an antiseptic solution (70% isopropyl alcohol) to prevent contamination.
• Sample Collection: A sterile, single-use needle is inserted into the vein, and blood is drawn into a serum separator tube (SST) containing a clot activator and gel barrier.
• Post-Collection Care: The needle is gently removed, and immediate pressure is applied to the site with a sterile cotton ball to prevent hematoma formation. A protective bandage is then applied.
• Safety and Comfort: The entire process takes less than five minutes. Patients may experience a mild, transient pinch during needle insertion, but the procedure is generally painless and safe.

When is an Extended Autoimmune Liver Profile Performed?

Evaluation of Unexplained Elevated Liver Enzymes

Physicians request this profile when a patient presents with persistently elevated liver transaminases (ALT and AST) or cholestatic markers (ALP and GGT) that cannot be attributed to common causes such as viral hepatitis, non-alcoholic fatty liver disease (NAFLD), alcohol abuse, or drug-induced liver injury. Identifying an autoimmune etiology early is critical to initiating targeted immunosuppressive therapy and preventing irreversible parenchymal damage.

Investigation of Suspected Autoimmune Hepatitis (AIH)

This profile is indicated when clinical symptoms point toward Autoimmune Hepatitis. AIH can present acutely or insidiously with symptoms such as chronic fatigue, fluctuating jaundice, arthralgia, pruritus, and hepatomegaly. Because AIH can progress rapidly to liver failure if untreated, the detection of specific markers like ASMA, LKM-1, or SLA/LP is vital for confirming the diagnosis and differentiating between Type 1 and Type 2 AIH.

Diagnosis of Primary Biliary Cholangitis (PBC)

Primary Biliary Cholangitis is a chronic cholestatic disease characterized by the progressive destruction of intrahepatic small bile ducts. Physicians order the Extended Autoimmune Liver Profile to detect Antimitochondrial Antibodies (AMA), specifically the AMA-M2 subtype, which is the diagnostic hallmark of PBC. Early detection allows for the timely initiation of Ursodeoxycholic Acid (UDCA) therapy, which significantly improves long-term survival.

Assessment of Overlap Syndromes

In some clinical scenarios, patients exhibit overlapping features of both autoimmune hepatitis and cholestatic liver diseases (PBC or PSC). The Extended Autoimmune Liver Profile evaluates multiple antibodies simultaneously, allowing clinicians to identify these complex overlap syndromes. Accurate characterization is essential because these patients typically require combination therapies involving both immunosuppressants and bile acid therapies.

Monitoring Treatment Response and Disease Progression

For patients with established autoimmune liver diseases, serial testing of specific autoantibody titers and associated liver function markers helps clinicians assess the efficacy of therapeutic interventions. A significant decline in antibody levels, alongside the normalization of liver enzymes, indicates a favorable response to immunosuppressive or immunomodulatory regimens, whereas rising titers may suggest a disease flare or non-compliance.

What Does an Extended Autoimmune Liver Profile Detect?

The Extended Autoimmune Liver Profile evaluates a highly specific array of autoantibodies and laboratory findings, including:

• Antinuclear Antibodies (ANA): Frequently positive in Autoimmune Hepatitis Type 1, presenting in various immunofluorescence patterns.
• Anti-Smooth Muscle Antibodies (ASMA): A key diagnostic marker for Autoimmune Hepatitis Type 1, targeting filamentous actin (F-actin).
• Anti-F-Actin Antibodies: A highly specific subset of ASMA associated with severe liver inflammation in AIH Type 1.
• Antimitochondrial Antibodies (AMA): The primary diagnostic marker for Primary Biliary Cholangitis, present in over 95% of cases.
• AMA-M2 Subtype: Highly specific antibodies targeting the E2 subunit of the pyruvate dehydrogenase complex in PBC.
• Anti-Liver Kidney Microsomal-1 (LKM-1) Antibodies: The definitive serological marker for Autoimmune Hepatitis Type 2, targeting cytochrome P450 2D6.
• Anti-Liver Cytosol-1 (LC-1) Antibodies: A specific marker for Autoimmune Hepatitis Type 2, often correlating with severe, active liver disease in younger patients.
• Anti-Soluble Liver Antigen/Liver-Pancreas (SLA/LP) Antibodies: Highly specific for Autoimmune Hepatitis, often predicting a more severe clinical course and tendency to relapse.
• Anti-gp210 Antibodies: A nuclear pore glycoprotein antibody associated with AMA-negative PBC and a higher risk of progression to hepatic failure.
• Anti-sp100 Antibodies: A nuclear dot protein antibody highly specific for PBC, aiding in the diagnosis of AMA-negative cases.
• Anti-Ro-52 Antibodies: Often detected in association with other autoimmune liver markers, indicating systemic autoimmune activity.
• Atypical p-ANCA: Perinuclear anti-neutrophil cytoplasmic antibodies, frequently found in patients with Autoimmune Hepatitis and Primary Sclerosing Cholangitis.
• Hypergammaglobulinemia: Elevated levels of total immunoglobulin G (IgG), a classic immunological finding in active Autoimmune Hepatitis.
• Hepatocellular Injury Markers: Concomitant evaluation of elevated Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST).
• Cholestatic Injury Markers: Concomitant evaluation of elevated Alkaline Phosphatase (ALP) and Gamma-Glutamyl Transferase (GGT).
• Serum Bilirubin Levels: Assessment of conjugating and excretory capacity of the liver, indicating the severity of cholestasis or parenchymal damage.
• Serum Albumin Levels: An indicator of the liver’s synthetic function, which may decline in advanced chronic autoimmune liver disease.
• Prothrombin Time (PT/INR): Evaluation of coagulation factor synthesis, serving as a critical marker of liver synthetic reserve.
• Autoimmune Hepatitis Type 1 vs Type 2 Differentiation: Clear serological distinction based on the presence of ANA/ASMA versus LKM-1/LC-1.
• AMA-Negative PBC Identification: Diagnosis of PBC in the absence of classical AMA, utilizing gp210 and sp100 markers.
• Overlap Syndrome Serology: Co-positivity of AIH and PBC-specific antibodies, guiding specialized clinical management.
• Prognostic Risk Stratification: Identification of high-risk antibody profiles (such as gp210 positivity) that correlate with rapid progression to cirrhosis.

Turnaround Time and Report Access at Test Zone Diagnostic Center

At Test Zone Diagnostic Center in Peshawar, Pakistan, we understand that timely diagnostic results are critical for patient management. The Extended Autoimmune Liver Profile involves complex, multi-step immunological assays that require meticulous processing and quality control. Typically, the verified reports are available within 3 to 5 working days from the time of sample collection.

Patients and referring physicians are notified via SMS as soon as the results are finalized. Reports can be accessed securely online through the Test Zone Diagnostic Center patient portal, allowing for immediate viewing and downloading. Physical copies of the reports can also be collected directly from our main diagnostic facility or designated collection centers across the region.

Extended Autoimmune Liver Profile Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Antinuclear Antibodies (ANA)	Negative (Titer < 1:40)	Positive (Titer >= 1:80), suggestive of Autoimmune Hepatitis Type 1 or systemic autoimmunity.
Anti-Smooth Muscle Antibodies (ASMA)	Negative (Titer < 1:20)	Positive (Titer >= 1:40), highly suggestive of Autoimmune Hepatitis Type 1.
Antimitochondrial Antibodies (AMA-M2)	Negative (< 20 RU/ml)	Positive (>= 20 RU/ml), diagnostic hallmark of Primary Biliary Cholangitis (PBC).
Anti-LKM-1 Antibodies	Negative (< 20 RU/ml)	Positive (>= 20 RU/ml), diagnostic for Autoimmune Hepatitis Type 2.
Anti-LC-1 Antibodies	Negative (< 20 RU/ml)	Positive (>= 20 RU/ml), specific for Autoimmune Hepatitis Type 2, correlates with active disease.
Anti-SLA/LP Antibodies	Negative (< 20 RU/ml)	Positive (>= 20 RU/ml), highly specific for Autoimmune Hepatitis, associated with severe course.
Anti-gp210 / Anti-sp100	Negative	Positive, diagnostic for AMA-negative PBC; gp210 correlates with poor prognosis.
Total Immunoglobulin G (IgG)	Normal range (700 – 1600 mg/dL)	Elevated levels (Hypergammaglobulinemia), indicating active autoimmune liver inflammation.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Test Zone Diagnostic Center for Extended Autoimmune Liver Profile?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly qualified pathologists and technologists specializing in advanced immunology.
• Patient-Focused Care: We prioritize patient comfort, safety, and clear communication throughout the diagnostic process.
• Quality Diagnostic Services: Test Zone Diagnostic Center adheres to strict internal and external quality control protocols to ensure clinical accuracy.
• Professional Reporting: Our diagnostic reports are comprehensive, structured, and easy for clinicians to interpret.
• Modern Diagnostic Approach: We utilize advanced ELISA and line immunoassay technologies for precise autoantibody detection.
• Comfortable Environment: Our state-of-the-art facility in Peshawar provides a clean, professional, and welcoming environment for patients.
• Convenient Location: Easily accessible main facility and collection points across Peshawar, Pakistan.
• Commitment to Accurate Diagnosis: We are dedicated to providing reliable, evidence-based diagnostic insights to support effective patient care.